0001358403-16-000274.txt : 20160923 0001358403-16-000274.hdr.sgml : 20160923 20160923185743 ACCESSION NUMBER: 0001358403-16-000274 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160921 FILED AS OF DATE: 20160923 DATE AS OF CHANGE: 20160923 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BELLICUM PHARMACEUTICALS, INC CENTRAL INDEX KEY: 0001358403 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 201450200 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2130 WEST HOLCOMBE BOULEVARD STREET 2: SUITE 800 CITY: HOUSTON STATE: TX ZIP: 77030 BUSINESS PHONE: (832) 384-1100 MAIL ADDRESS: STREET 1: 2130 WEST HOLCOMBE BOULEVARD STREET 2: SUITE 800 CITY: HOUSTON STATE: TX ZIP: 77030 FORMER COMPANY: FORMER CONFORMED NAME: BELLICUM PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060405 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Spencer David M. CENTRAL INDEX KEY: 0001627362 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36783 FILM NUMBER: 161900756 MAIL ADDRESS: STREET 1: C/O BELLICUM PHARMACEUTICALS, INC. STREET 2: 2130 W. HOLCOMBE BLVD., STE. 800 CITY: HOUSTON STATE: TX ZIP: 77030 4 1 wf-form4_147467145111371.xml FORM 4 X0306 4 2016-09-21 0 0001358403 BELLICUM PHARMACEUTICALS, INC BLCM 0001627362 Spencer David M. C/O BELLICUM PHARMACEUTICALS, INC. 2130 W. HOLCOMBE BLVD., STE. 800 HOUSTON TX 77030 0 1 0 0 Chief Scientific Officer Common Stock 2016-09-21 4 S 0 300 20.04 D 172282 D Common Stock 2016-09-22 4 S 0 10000 19.6832 D 162282 D Common Stock 2016-09-23 4 S 0 6200 20.1891 D 156082 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 21, 2016 by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.15 to $20.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. /s/ David M. Spencer 2016-09-23